NCT06277037

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Arbutus Biopharma Corporation · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).

Conditions

• Long Term Follow-up

Interventions

Type	Name	Description
OTHER	Non-interventional	This is a rollover study

Timeline

• Start date: 2024-07-11
• Primary completion: 2029-08-30
• Completion: 2029-10-30
• First posted: 2024-02-26
• Last updated: 2024-11-27

Locations

18 sites across 7 countries: United States, Australia, Hong Kong, Moldova, South Korea, Taiwan, United Kingdom